Kyowa Hakko Kirin

Kyowa Hakko Kirin Co., Ltd.

Type	Public KK
Traded as	TYO: 4151 FWB: KY4 Nikkei 225 Component
Industry	Pharmaceuticals Biotechnology
Founded	July 1, 1949
Headquarters	Ohtemachi Building, 1-6-1, Ōtemachi, Chiyoda-ku, Tokyo 100-8185, Japan
Key people	Nobuo Hanai, (CEO and President)
Products	Biochemicals Biosimilars Diagnostics Pharmaceuticals
Revenue	$ 3.548 billion USD (FY 2013) (¥ 340.61 billion JPY) (FY 2013)
Net income	$ 31.32 million USD (FY 2013) (¥ 30.07 billion JPY) (FY 2013)
Number of employees	7,152 (consolidated) (as of December 31, 2013)
Parent	Kirin Holdings Company, Limited
Subsidiaries	47 (33 in Japan and 14 overseas countries)
Website	Official website
Footnotes / references [1][2][3]

Kyowa Hakko Kirin Co., Ltd. (協和発酵キリン株式会社 Kyōwa Hakkō Kirin Kabushiki Kaisha) is a Japanese pharmaceutical and biotechnology company under the Kirin Holdings, and is among the 40 largest in the world by revenue. The company is headquartered in Chiyoda-ku, Tokyo and is a member of the Nikkei 225 stock index.^[4][5]

History

On July 1, 1949 the forerunner of the present company, Kyowa Hakko Kogyo Co., Ltd. is established. Following the merger with Kirin Pharma Co., Ltd., on October 1, 2008 the company changed its name to its present.

On July 11, 2014, the KHK subsidiary, ProStrakan Group, acquired Archimedes Pharma from the Novo Nordisk Foundation for $394 million ^[6]

Business segments and products

• Pharmaceuticals business
  • Central nervous system medicines
  • Immunology/Allergy medicines
  • Nephrology medicines
    • ESPO / NESP / Aranesp
    • REGPARA
  • Oncology medicines:
    • ABSTRAL
    • GRAN / Peglasta / Neulasta
    • LEUNASE
    • Mitomycin-C
    • SANCUSO
  • Diagnostics
    • In vitro diagnostic reagents, analyzers and companion diagnostics
• Bio-Chemicals business
  • Biosimilars
  • Amino acids, nucleic acids and related compounds, health care products and other active pharmaceutical ingredients
  • Vitamins, minerals, peptides and plant growth regulators^[7]

References

1. "Kyowa Hakko Kirin Company Overview". Kyowa Hakko Kirin. Retrieved March 14, 2014.
2. "Kyowa Hakko Kirin Corporate Profile" (PDF). Kyowa Hakko Kirin. Retrieved March 14, 2014.
3. "Kyowa Hakko Kirin Annual Report 2012". Kyowa Hakko Kirin. Retrieved March 14, 2014.
4. "Components:Nikkei Stock Average". Nikkei Inc. Retrieved January 20, 2015.
5. "Top 50 Pharma Companies by 2012 Revenue". Wildwood Ventures Ltd. Retrieved March 14, 2014.
6. "ProStrakan Acquires Archimedes Pharma for $394M". Genetic Engineering & Biotechnology News. Mary Ann Liebert, Inc. July 11, 2014. Retrieved January 20, 2015.
7. "FY 2013 Consolidated Financial Summary". Kyowa Hakko Kirin. Retrieved March 14, 2014.

External links

• Official website